Despite these promising developmental milestones, financial markets have maintained a cautious stance toward Corcept. Within a 30-day period, consensus earnings per share estimates for 2025 declined ...

As markets remain fixated on emerging AI leaders, conventional software enterprises are being left behind. Even on days when it posted modest gains, Salesforce failed to keep pace with the broader ...

SunHydrogen presents investors with a confounding market puzzle. While the hydrogen technology company continues to announce significant operational milestones and demonstrate commercially viable ...

Warren Buffett's sprawling investment conglomerate is executing a significant strategic shift within its massive investment portfolio. This repositioning occurs against a backdrop of modest market ...

Defense contractor Lockheed Martin is navigating a complex period marked by significant financial setbacks and mounting legal pressure. The company finds itself at a crossroads as institutional ...

Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin ...

Civinity has exercised its early redemption right and repurchased €3.69 millions of its private bond issue from INVL Bridge Finance ahead of schedule. The bonds, issued in June 2025, carried a zero ...

Vicarious Surgical has demonstrated considerable cost discipline, reducing its operating expenses by 24% year-over-year to $13.5 million. This austerity measure helped narrow the net loss to $13.2 ...

In contrast to the strong fundamental data, technical indicators present a more mixed and cautious perspective. Short-term momentum (1-5 days) appears positive, while medium-term signals (5-20 days) ...

Cruise operator Carnival is staging a remarkable financial recovery, but its impressive stock performance masks a series of complex refinancing maneuvers. As shares approach their annual peak, ...

Market reaction has been unequivocal. Following the earnings release, BigBear.ai shares plummeted over 21 percent, extending their decline to more than 30 percent over the past month. The sell-off has ...

Beyond its lead drug candidate, Aldeyra is advancing a second promising asset. The compound ADX-2191, developed for rare retinal disorders, has secured both Orphan Drug and Fast Track designations ...